Union Bank of India announces the extension of the term of its Executive Director, Shri Ramasubramanian S., beyond his current term ending November 20, 2025. The extension will continue until his superannuation on June 30, 2027, or until further orders, whichever comes earlier. This decision ensures continuity in the bank’s leadership.

Executive Leadership Continuity

Union Bank of India has extended the tenure of Executive Director, Shri Ramasubramanian S., confirming leadership stability for the coming period. The extension was formalized on September 16, 2025.

Term Extension Details

The term of Shri Ramasubramanian S. has been extended beyond November 20, 2025, the date of his originally notified term. He will now serve until his superannuation, effective June 30, 2027. This extension remains valid unless superseded by further directives.

Source: BSE

Vishal Mega Mart has scheduled a store visit for investors and analysts on September 19, 2025. This visit will allow investors/analysts to gain firsthand insights into the company’s operations at a subsidiary store. The meeting is scheduled to commence at 11:00 AM (IST) onwards. The announcement specifies that unpublished price-sensitive information will not be disclosed during the interactions.

Store Visit for Investors

Vishal Mega Mart is hosting a store visit for investors and analysts. The visit is scheduled for September 19, 2025 and is designed to provide stakeholders with an opportunity to assess the company’s operations. This meeting allows investors and analysts to engage directly with the company’s operational environment.

Meeting Details

The store visit is scheduled to begin at 11:00 AM (IST) onwards. The nature of the meeting is described as a Group Meeting. It has been explicitly stated that no unpublished price-sensitive information will be shared during the visit.

Please note that the schedule for the meeting is subject to change based on the exigencies of the participants and the company. Investors and analysts are advised to consider this potential for alteration when planning their attendance.

Source: BSE

Union Bank of India has announced the extension of Shri Nitesh Ranjan’s term as Executive Director for a further period of three years beyond his current term. The extension, effective until 09.03.2026 or until further notice, was approved on September 15, 2025. This decision ensures continuity in leadership at the executive level for the bank.

Executive Leadership Continuity

Union Bank of India has officially extended the term of Shri Nitesh Ranjan as Executive Director. This extension ensures leadership stability at a crucial executive level within the organization.

Term Extension Details

The term of Shri Nitesh Ranjan has been extended for a period of three years beyond his currently notified term, which concludes on 09.03.2026. The extension is effective from September 15, 2025 and will continue until 09.03.2026, or until further orders are issued.

Source: BSE

India Ratings has upgraded Alivus Life Sciences’s long-term bank loan facilities rating to ‘IND AA’ from ‘IND AA-‘, with a Stable Outlook. The short-term rating is affirmed at ‘IND A1+’. This upgrade reflects Alivus’s healthy revenue visibility, strong EBITDA margins, and a net cash position in FY25. Capacity utilization remains high, benefiting from its association with Glenmark Pharmaceuticals and volume supply contracts extending to FY29.

Rating Upgrade Rationale

Alivus Life Sciences (ALS) has received an upgrade in its long-term rating to ‘IND AA’ with a Stable Outlook, reflecting the company’s strong financial performance and market position. The upgrade is driven by healthy revenue visibility and strong EBITDA margins in FY25. The company’s short-term rating has been affirmed at ‘IND A1+’.

Key Financial Highlights

During FY25-Q1FY26, ALS maintained strong operational performance despite pricing headwinds in the active pharmaceutical ingredient (API) market. The company has demonstrated high capacity utilization (above 95%) despite an 86% increase in capacity between FY22-FY25. Revenue for FY25 reached INR23,869 million.

Strategic Advantages

ALS benefits from its association with Glenmark Pharmaceuticals Limited, with supply contracts extending until FY29. The company is also a part of the Nirma Limited group, enhancing its financial flexibility. The company’s focus on niche and complex portfolios has allowed it to maintain healthy EBITDA margins. As of FY25, it has a portfolio of 165 molecules and a pipeline of 49 new products.

Future Outlook

Despite planned capital expenditures to almost double capacities, ALS is expected to maintain strong credit metrics due to minimal reliance on external funding. The company remains net cash positive and is strategically positioned to capitalize on the growing HPAPI market, which is expected to reach USD45.70 billion by 2030.

Financial Performance Details

In FY25, the company’s EBITDA margins remained healthy at 28.6%. The company’s research and development expenditure stood at INR805 million, accounting for 3.4% of total revenue. As of end-June 2025, ALS filed over 569 drug master filings (DMFs) across various markets. The company had healthy cash reserves of INR5,487 million at the end of FY25.

Source: BSE

Union Bank of India will conduct an Investor/Analyst Meet with Angel One Investment Managers & Advisors Private Limited on September 19, 2025. The meeting will be conducted in a one-on-one, virtual format. Presentation copy for the meeting will not be shared.

Investor/Analyst Meeting Announcement

Union Bank of India has announced an upcoming Investor/Analyst Meet scheduled for September 19, 2025.

Meeting Details

The meeting will be held with Angel One Investment Managers & Advisors Private Limited.

Key Information:

• Date: September 19, 2025
• Mode: One-to-one and Virtual

Additional Information

Details regarding registration and specific platform requirements for the meet will be provided virtually. A presentation copy for the meeting will not be available. Bank will be referring to publicly available documents for discussions during the meet.

Source: BSE

Officials from the Competition Commission of India (CCI) visited Jindal Saw’s Delhi offices between September 15, 2025, and September 16, 2025, concerning an ongoing investigation. Jindal Saw has stated it is extending full cooperation to the authorities during this process and will continue to update the Stock Exchange(s) on further developments. Certain media channels have also reported on this matter.

CCI Visit to Delhi Offices

Between September 15, 2025, and September 16, 2025, officials from the Competition Commission of India (CCI) visited the offices of Jindal Saw in Delhi. This visit is related to an investigation by the CCI.

Company’s Cooperation

Jindal Saw has stated that they have extended full cooperation to the authorities during this investigation. The company has also stated that it will continue to keep the Stock Exchange(s) updated on further developments.

Media Reporting

Certain media and news channels have reported on this matter.

Source: BSE

Life Insurance Corporation of India (LIC) has announced that representatives of the Corporation participated in an Investor Meet organized by Jefferies – 4th India Forum. During the meet, no unpublished price-sensitive information was shared or discussed. The event took place on September 16, 2025, at Hotel Oberoi, Gurugram, Haryana, involving group and one-on-one meetings.

Participation in Investor Meet

Life Insurance Corporation of India (LIC) representatives engaged in an Analyst/Institutional Investor Meet/Conference organized by Jefferies – 4th India Forum.

Details of the Investor Meet

The Investor Meet took place on September 16, 2025, at Hotel Oberoi, Gurugram, Haryana. The format included group and one-on-one meetings with investors.

Information Disclosure

During the Investors’ Meet, the representatives of LIC did not share or discuss any unpublished price-sensitive information. This communication follows their earlier filing dated September 10, 2025.

Source: BSE

Indian Overseas Bank (IOB) has announced the extension of tenure for Executive Director, Shri Joydeep Dutta Roy. The extension is effective beyond October 20, 2025, for a period of three years, or until further notice, whichever occurs earlier. This decision was made under the powers conferred by relevant banking regulations and approved by the Central Government.

Tenure Extension Announcement

Indian Overseas Bank (IOB) has officially declared the extension of the term of office for its Executive Director, Shri Joydeep Dutta Roy, effective beyond October 20, 2025. The decision, announced on September 16, 2025, pertains to Shri Joydeep Dutta Roy (DOB: 01.07.1972).

Terms of Extension

Shri Joydeep Dutta Roy’s tenure is extended for a period of three years beyond October 20, 2025, or until further orders, whichever is earlier. This extension has been approved under the powers conferred by clause (a) of sub-section (3) of section 9 of the Banking Companies (Acquisition and Transfer of Undertakings) Act, 1970, and subsequent amendments. The Central Government approved the extension via Notification No.4/4(i)/2024-BO.I dated September 15, 2025.

Source: BSE

Godrej Industries has approved the issuance of up to ₹800 Crore in Rated, Listed, Unsecured, Redeemable, Non-Convertible Debentures (NCDs) through private placement. This issuance includes two series of debentures, each with a face value of ₹1,00,000, with the option to retain oversubscription. The funds raised are expected to support the company’s financial strategies and growth initiatives. The decision was made on September 16, 2025.

Details of the Debenture Issuance

Godrej Industries has announced the approval of a private placement for Rated, Listed, Unsecured, Redeemable, Non-Convertible Debentures (NCDs) amounting to ₹800 Crore. The approval was granted on September 16, 2025.

Series 1 Debentures

The company will issue up to 27,500 debentures with a face value of ₹1,00,000 each, aggregating up to ₹275 Crore. An option to retain oversubscription of up to ₹125 Crore is available, bringing the potential total to ₹400 Crore under “SERIES 1 DEBENTURES”.

Series 2 Debentures

Similar to Series 1, Series 2 will also involve the issuance of up to 27,500 debentures, each with a face value of ₹1,00,000, totaling ₹275 Crore. The oversubscription option allows for an additional ₹125 Crore, reaching a total of ₹400 Crore under “SERIES 2 DEBENTURES”.

Purpose of the Issuance

The funds raised through this private placement are intended to support Godrej Industries’ ongoing financial requirements and strategic growth objectives.

Source: BSE